Hemophagocytic lymphohistiocytosis (HLH) is a lethal disorder of immune dysregulation. Successful allogeneic BMT is the only therapy that has produced long-term disease-free survival. However, for patients with active HLH the outcome of BMT remains poor when compared with those transplanted in remission. We describe a patient with active, recurrent HLH treated with highdose chemotherapy and related allogeneic peripheral blood stem cell (PBSC) transplantation. Hematologic recovery was rapid and the post-transplant course was uncomplicated. The patient is alive and well 2. years after transplant. Allogeneic PBSC transplantation may deserve further evaluation as an alternative source of stem cells for transplantation in patients with active HLH.
Hemophagocytic lymphohistiocytosis (HLH) is a lethal disorder of immune dysregulation usually affecting infants and young children. Patients present with fever, hepatosplenomegaly, pancytopenia, coagulopathy and central nervous system involvement. Treatment frequently includes steroids, epipodophyllotoxins, cyclosporine and intrathecal methotrexate but lasting remission is rare. 1, 2 Apparent cure has only been seen after allogeneic BMT. However, patients with active disease at the time of BMT did poorly, with a high incidence of disease recurrence and treatmentrelated mortality. This led some to question whether such patients should not undergo BMT, as their survival may be no better than that after conventional therapy. 3 We report our experience of a successful allogeneic transplant using PBSC in a child with refractory HLH and suggest this may be an alternative source of hematopoietic stem cells for treatment of this disorder. 
Case report
A 3-year-old girl with HLH was referred to our center for allogeneic stem cell transplantation. Her disease had recurred twice within 6 months of diagnosis despite treatment with steroids, cyclosporine and VP-16. She had high fever and significant hepatosplenomegaly on admission to our center. The conditioning regimen consisted of etoposide 13.3 mg/kg i.v. on days Ϫ9, Ϫ8, Ϫ7; busulfan 1.5 mg/kg every 6 h p.o. on days Ϫ6, Ϫ5, Ϫ4; and cyclophosphamide 60 mg/kg i.v. on days Ϫ3, Ϫ2. The donor was a 5-yearold HLA-identical brother, who underwent rhG-CSF mobilization and a single PBSC apheresis procedure. The PBSC product infused contained 8. Ϫ cells/kg of the recipient's body weight, respectively. Graftversus-host disease (GVHD) prophylaxis consisted of cyclosporine 3 mg/kg/day i.v. and methylprednisolone 0.5 mg/kg/day i.v. The post-transplant course was uncomplicated except for febrile neutropenia. Myeloid engraftment was noted on day 11, and the platelet count exceeded 20 000/mm 3 on day 14. She was discharged from the hospital on day 20. No evidence of acute or chronic GVHD developed. The patient remains in continuous remission 30 months post-transplant, with normal biochemical parameters and NK cell function. Cytogenetic analysis shows 100% donor (male) karyotype.
Discussion
The etiology of HLH is unknown but is associated with hypercytokinemia and decreased natural killer cell function.
1,2 The disease often responds transiently to a variety of treatment modalities such as chemotherapy (epipodophyllotoxin), immunosuppression (cyclosporine, steroids, antithymocyte globulin), and immunomodulation (interferon, immunoglobulins) before further progression.
2 Highdose chemotherapy followed by allogeneic bone marrow transplantation can be curative, but the results in patients with active HLH are poor. In a report by Baker et al, 3 eight of 14 patients transplanted in clinical remission were longterm survivors; but only one of six patients with active HLH remained alive. Similarly, all three patients treated in second partial remission reported by Blanche et al 4 died of early relapse. The exact mechanism of action of allogeneic BMT in HLH is not known. Complete marrow ablation may not be required for cure. Partial chimeric states were observed after allogeneic transplantation in five of six patients who appeared well and free of disease. 5 There were also reports of patients who had early graft rejection, autologous reconstitution and prolonged clinical remission with 2 or without subsequent disease progression. 6 Similarly, Ohga et al 7 reported prolonged resolution of HLH 30 months after an autologous PBSC transplant in a patient who had failed prior therapies.
Allogeneic PBSC has recently been evaluated as a source of hematopoietic stem cells for transplantation. The large numbers of hematopoietic progenitors enhance durable engraftment and lead to rapid hematologic reconstitution. Transplantation using PBSC in high-risk leukemia patients was associated with reduction in early treatment-related mortality. 8 We have reported the lymphoid and NK cells in a stem cell graft to be 27.4-and 19.4-fold higher than that in a marrow harvest. 9 Immune recovery is improved after allogeneic PBSC transplantation. 10 Both of these features may be particularly beneficial to patients with HLH, especially those with active disease and poor performance status. Our patient was the first reported to have received allogeneic PBSC alone for transplantation of HLH, and her post-transplant recovery was rapid, similar to the experience of such transplants for other diagnoses. 10 We suggest that allogeneic PBSC transplantation deserves further evaluation in patients with HLH.
